Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 106

Sort by

Sort Order Select

Journal Articles

Addition of Myeloablative Doses of Total Marrow Irradiation (TMI) to Myeloablative Fludarabine/Busulfan Conditioning for Allogeneic HSCT in Patients with High-Risk AML, CML, or Myelodysplastic Syndrome: A Phase II Clinical Trial

Lucas Maahs, Matthew Koshy, Karen Sweiss, Kang-hyun Ahn, Zhengjia Chen, Chukwuemeka Uzoka, Carlos Galvez, Paul Rubinstein, John Quigley, Santosh L. Saraf, Ana Maria Avila Rodriguez, Bulent Aydogan, Nadim Mahmud, Damiano Rondelli

Blood (2023) 142 (Supplement 1): 4897.

https://doi.org/10.1182/blood-2023-179270

Published: 2023

Journal Articles

RAMP up: Risk Adapted Post-Autologous Transplant Maintenance Therapy in MRD Positive Myeloma Patients

Karen Sweiss, Craig C. Hofmeister, Ghulam Rehman Mohyuddin, Amandeep Godara, Brian McClune, Damiano Rondelli, Danny Hadidi, David Chan, Matias Eugenio Sanchez, Min Hai, Mitch A. Phelps, Chukwuemeka Uzoka, Douglas Sborov

Blood (2023) 142 (Supplement 1): 4974.

https://doi.org/10.1182/blood-2023-191148

Published: 2023

Journal Articles

Free from Drug Therapy in Multiple Myeloma (FREEDMM): MRD-Based Cessation of Maintenance

Ana Maria Avila Rodriguez, Danny Hadidi, Craig C. Hofmeister, John Quigley, Maria Zappia, Maxim Frolov, Elizaveta Benevolenskaya, Matias Eugenio Sanchez, Shrihari Kadkol, Douglas Sborov, Damiano Rondelli, Chukwuemeka Uzoka, Karen Sweiss

Blood (2023) 142 (Supplement 1): 3395.

https://doi.org/10.1182/blood-2023-190011

Published: 2023

Journal Articles

Help for Ukrainian Hematology Patients (HUP) - a Global Initiative Supporting the Establishment of Hematology Centers and Hematopoietic Cell Transplantation Programs in a Time of War

Blood (2023) 142 (Supplement 1): 264.

https://doi.org/10.1182/blood-2023-185883

Published: 2023

Journal Articles

Exagamglogene Autotemcel for Severe Sickle Cell Disease

Blood (2023) 142 (Supplement 1): 1052.

https://doi.org/10.1182/blood-2023-190139

Published: 2023

Journal Articles

Chronic Opioid Use Is Highly Prevalent and Associated with Inferior Survival in Myeloma Patients in Remission after Autologous Transplant

Karen Sweiss, Craig C Hofmeister, John G. Quigley, Jaleel G. Sweis, Kaily Kurzweil, Douglas W. Sborov, Lisa Sharp, Gregory S Calip, Lucas Maahs, Ana Maria Avila, Chukwuemeka Uzoka, Elizabeth Ilo, Elliot Wolf, Damiano Rondelli, Pritesh Patel

Blood (2022) 140 (Supplement 1): 5252–5253.

https://doi.org/10.1182/blood-2022-171045

Published: 2022

Journal Articles

G-CSF Improves Stable Engraftment in Adults with Sickle Cell Disease Undergoing Nonmyeloablative Hematopoietic Stem Cell Transplantation

Lucas Maahs, Karen Sweiss, Pritesh Patel, Sally Campbell-Lee, Nadim Mahmud, Victor R. Gordeuk, Damiano Rondelli, Santosh L. Saraf

Blood (2022) 140 (Supplement 1): 4747–4748.

https://doi.org/10.1182/blood-2022-160050

Published: 2022

Journal Articles

Pre-Transplant Assessment of Adult Sickle Cell Patients Shows a High Prevalence of Psychosocial Frailties before Allogeneic Stem Cell Transplant

Karen Sweiss, Santosh L. Saraf, Alison Doane, Monika Mandava, Ryan Sun, Mahir Khan, Zacharie Paul Charles Hamilton, Jaleel G. Sweis, Victor R. Gordeuk, Damiano Rondelli, Lisa Sharp, Pritesh Patel

Blood (2022) 140 (Supplement 1): 5123–5124.

https://doi.org/10.1182/blood-2022-171103

Published: 2022

Journal Articles

Free from Maintenance Drug Therapy in Multiple Myeloma (The FREEDMM Trial): A Pilot Study of Minimal Residual Disease (MRD)-Driven Discontinuation of Maintenance

Karen Sweiss, Craig C Hofmeister, Maria Zappia, Maxim Frolov, Elizaveta Benevolenskaya, John G. Quigley, Shrihari Kadkol, Douglas W. Sborov, Damiano Rondelli, Pritesh Patel

Blood (2022) 140 (Supplement 1): 7304–7305.

https://doi.org/10.1182/blood-2022-170936

Published: 2022

Journal Articles

Long-Term Adverse Events of Total Marrow Irradiation (TMI)-Based Conditioning Chemotherapy in Hematopoietic Stem Cell Transplant Recipients Treated on a Phase I/II Trial

Lucas Maahs, Pritesh Patel, Karen Sweiss, Chukwuemeka Uzoka, Nadim Mahmud, Ana Maria Avila, Matthew Koshy, Damiano Rondelli

Blood (2022) 140 (Supplement 1): 12913–12914.

https://doi.org/10.1182/blood-2022-163424

Published: 2022

Journal Articles

Safety and Efficacy of the Addition of the Protein Translation Inhibitor Omacetaxine to Induction with Cytarabine and Idarubicin in Newly Diagnosed AML

Samin Houshyar, Betul Gok Yavuz, Pritesh Patel, Nadim Mahmud, Karen Sweiss, Irum Khan, Santosh L. Saraf, Damiano Rondelli, Anwar Khan, John G. Quigley

Blood (2022) 140 (Supplement 1): 5957–5958.

https://doi.org/10.1182/blood-2022-170100

Published: 2022

Journal Articles

Phase 1 Trial of AUC-Targeted Melphalan in Myeloma Patients Undergoing Autologous Transplant (The MyMel Study)

Karen Sweiss, Pritesh Patel, Janet Guo, Kyeongmin Kim, Kasey Hill, Nicole Abbott, Jeremy Johnson, Donald Irby, John G. Quigley, Damiano Rondelli, R Donald Harvey, Ajay K. Nooka, Madhav Dhodapkar, Jonathan L. Kaufman, Nisha S. Joseph, Sagar Lonial, Douglas W. Sborov, Mitch A Phelps, Craig C Hofmeister

Blood (2022) 140 (Supplement 1): 5988–5990.

https://doi.org/10.1182/blood-2022-170778

Published: 2022

Journal Articles

Efficacy and Safety of a Single Dose of Exagamglogene Autotemcel for Severe Sickle Cell Disease

Haydar Frangoul, Franco Locatelli, Monica Bhatia, Markus Y. Mapara, Lyndsay Molinari, Akshay Sharma, Stephan Lobitz, Mariane de Montalembert, Damiano Rondelli, Martin Steinberg, Mark C. Walters, Suzan Imren, Lanju Zhang, Anjali Sharma, Yang Song, Christopher Simard, William Hobbs, Stephen Grupp

Blood (2022) 140 (Supplement 1): 29–31.

https://doi.org/10.1182/blood-2022-162353

Published: 2022

Journal Articles

A randomized phase 3 trial of interferon-α vs hydroxyurea in polycythemia vera and essential thrombocythemia

Blood (2022) 139 (19): 2931–2941.

https://doi.org/10.1182/blood.2021012743

Published: 2022

Includes: Supplemental data

Journal Articles

Chronic Opioid Use Is Highly Prevalent in Patients Undergoing Allogeneic Transplant and Impacts Long Term Outcomes

Karen Sweiss, Kaily Kurzweil, Gregory S Calip, Lisa Sharp, Nadia Nabulsi, Mahir Khan, Damiano Rondelli, Pritesh R Patel

Blood (2021) 138 (Supplement 1): 1823.

https://doi.org/10.1182/blood-2021-154472

Published: 2021

Journal Articles

Long-Term Cardiac Effects of Successful Non-Myeloablative HLA-Matched Sibling Transplants in Sickle Cell Disease

Vandana Sachdev, My-Le Nguyen, Wen Li, Neal Jeffries, Shalini S Ramachandra, David Tofovic, Damiano Rondelli, Matthew Hsieh, Santosh L. Saraf, Courtney D. Fitzhugh

Blood (2021) 138 (Supplement 1): 2898.

https://doi.org/10.1182/blood-2021-148173

Published: 2021

Journal Articles

Social and Demographic Factors Contributing to COVID-19 Vaccine Hesitancy in Patients with Hematologic Malignancies

Karen Sweiss, Meredith Russell, Gregory S Calip, Ryan Nguyen, Meshaal Khan, Eshana Shah, Ronald Ng, Kaily Kurzweil, Mahir Khan, Ammarah Nadeem, Lisa Wendt, Nicole Fuchs, Elaine Trinh, Damiano Rondelli, Pritesh R Patel

Blood (2021) 138 (Supplement 1): 841.

https://doi.org/10.1182/blood-2021-154339

Published: 2021

Journal Articles

High Rates of Varicella Zoster Virus Antibody Seroconversion and Persistence after Administration of the Adjuvanted, Recombinant Varicella Zoster Vaccine in Multiple Myeloma Patients Undergoing Active Treatment

Karen Sweiss, PharmD, Gregory Sampang Calip, PharmD,MPH,PhD, Damiano Rondelli, MD, Pritesh Patel, MB, ChB

Blood (2020) 136 (Supplement 1): 50.

https://doi.org/10.1182/blood-2020-143342

Published: 2020

Journal Articles

Comparison of Individualized Versus MAP-Bayesian Predicted AUC of Busulfan in FluBu4 Treated Patients Undergoing Allogeneic Transplant

Karen Sweiss, PharmD, Eric Wenzler, Hung H Nguyen, MLS, Avadhut D Joshi, PhD, Rosa Yeh, PharmD, Gregory Sampang Calip, PharmD,MPH,PhD, Jeremy Johnson, PharmD, PhD, Donald Irby, PhD, Mitch A. Phelps, PhD, Damiano Rondelli, MD, Pritesh Patel, MB, ChB

Blood (2020) 136 (Supplement 1): 19–20.

https://doi.org/10.1182/blood-2020-143430

Published: 2020

Journal Articles

Increased DNA Repair Gene Expression Correlates with MYC Expression and Inferior Progression-Free Survival in Multiple Myeloma Patients

Karen Sweiss, PharmD, Benjamin G Barwick, PhD, Gregory Sampang Calip, PharmD,MPH,PhD, Damiano Rondelli, MD, Craig C Hofmeister, MDMPH, Pritesh Patel, MB, ChB

Blood (2020) 136 (Supplement 1): 48–49.

https://doi.org/10.1182/blood-2020-143422

Published: 2020

NARROW

Addition of Myeloablative Doses of Total Marrow Irradiation (TMI) to Myeloablative Fludarabine/Busulfan Conditioning for Allogeneic HSCT in Patients with High-Risk AML, CML, or Myelodysplastic Syndrome: A Phase II Clinical Trial

RAMP up: Risk Adapted Post-Autologous Transplant Maintenance Therapy in MRD Positive Myeloma Patients

Free from Drug Therapy in Multiple Myeloma (FREEDMM): MRD-Based Cessation of Maintenance

Help for Ukrainian Hematology Patients (HUP) - a Global Initiative Supporting the Establishment of Hematology Centers and Hematopoietic Cell Transplantation Programs in a Time of War

Exagamglogene Autotemcel for Severe Sickle Cell Disease

Chronic Opioid Use Is Highly Prevalent and Associated with Inferior Survival in Myeloma Patients in Remission after Autologous Transplant

G-CSF Improves Stable Engraftment in Adults with Sickle Cell Disease Undergoing Nonmyeloablative Hematopoietic Stem Cell Transplantation

Pre-Transplant Assessment of Adult Sickle Cell Patients Shows a High Prevalence of Psychosocial Frailties before Allogeneic Stem Cell Transplant

Free from Maintenance Drug Therapy in Multiple Myeloma (The FREEDMM Trial): A Pilot Study of Minimal Residual Disease (MRD)-Driven Discontinuation of Maintenance

Long-Term Adverse Events of Total Marrow Irradiation (TMI)-Based Conditioning Chemotherapy in Hematopoietic Stem Cell Transplant Recipients Treated on a Phase I/II Trial

Safety and Efficacy of the Addition of the Protein Translation Inhibitor Omacetaxine to Induction with Cytarabine and Idarubicin in Newly Diagnosed AML

Phase 1 Trial of AUC-Targeted Melphalan in Myeloma Patients Undergoing Autologous Transplant (The MyMel Study)

Efficacy and Safety of a Single Dose of Exagamglogene Autotemcel for Severe Sickle Cell Disease

A randomized phase 3 trial of interferon-α vs hydroxyurea in polycythemia vera and essential thrombocythemia

Chronic Opioid Use Is Highly Prevalent in Patients Undergoing Allogeneic Transplant and Impacts Long Term Outcomes

Long-Term Cardiac Effects of Successful Non-Myeloablative HLA-Matched Sibling Transplants in Sickle Cell Disease

Social and Demographic Factors Contributing to COVID-19 Vaccine Hesitancy in Patients with Hematologic Malignancies

High Rates of Varicella Zoster Virus Antibody Seroconversion and Persistence after Administration of the Adjuvanted, Recombinant Varicella Zoster Vaccine in Multiple Myeloma Patients Undergoing Active Treatment

Comparison of Individualized Versus MAP-Bayesian Predicted AUC of Busulfan in FluBu4 Treated Patients Undergoing Allogeneic Transplant

Increased DNA Repair Gene Expression Correlates with MYC Expression and Inferior Progression-Free Survival in Multiple Myeloma Patients

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only